AYTU BIOPHARMA, INC. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K reports on the 2018 annual meeting of stockholders for Aytu BioScience, Inc., held on June 27, 2018. The meeting addressed the fiscal year ended June 30, 2018. The company is incorporated in Delaware with principal executive offices in Englewood, Colorado.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Of the 35,883,069 shares outstanding, 27,180,123 shares were present or represented at the meeting. Key outcomes include:
- Director Elections: Five directors were elected by a plurality of votes cast: Joshua R. Disbrow, Gary V. Cantrell, Carl C. Dockery, John A. Donofrio, Jr., and Michael E. Macaluso. All received zero votes against.
- Authorized Shares Amendment: Stockholders did not approve an amendment to increase authorized common stock from 100,000,000 to 300,000,000 shares. The vote was 16,288,316 for, 10,321,933 against, and 569,874 abstaining.
- Reverse Stock Split: Stockholders approved an amendment to effect a reverse stock split at a ratio of up to 1-for-20, to be determined by the board. The vote was 18,053,733 for, 8,948,996 against, and 177,394 abstaining.
- Auditor Ratification: Stockholders ratified the appointment of EKS&H, LLLP as the independent registered public accounting firm. The vote was 22,207,381 for, 2,657,778 against, and 2,314,964 abstaining.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on financial performance, or a discussion of risks and contingencies beyond the voting results.
Investor Verification Checklist
- Verify the implementation timeline and specific ratio for the approved reverse stock split (up to 1-for-20).
- Review the company's capital structure strategy following the rejection of the authorized share increase.
- Confirm the impact of the reverse stock split on share price and trading liquidity.
- Check subsequent filings for the company's financial performance for the fiscal year ended June 30, 2018, as this 8-K contains no financial data.